Clinical trials: Sarcoma, Alveolar Soft Part, open to volunteers
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
This phase III trial compares chest computed tomography (CT) to chest x-ray (CXR) for lung surveillance after curative-intent resection of high-risk truncal-extremity soft tissue sarcoma.
- Conditions
- Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma, AJCC Grade 3 Sarcoma, Alveolar Soft Part Sarcoma
- Trial name
- NCT06526897
- Testing
- Biopsy, Chest Computed Tomography, Chest Radiography
- Volunteers
- 1,582 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type…
- Conditions
- Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma
- Trial name
- NCT05333458
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Sarcoma, Myxofibrosarcoma
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called…
- Conditions
- Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
- Trial name
- NCT04332874
- Testing
- Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Alveolar Soft Part Sarcoma
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or…
- Trial name
- NCT07548177
- Testing
- Benmelstobart injection combined with Anlotinib hydrochloride capsule
- Where
- 15 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.